Clinical, mammographic, and sonographic preoperative size measurements were correlated with the values obtained at pathologic examination in a series of 31 patients with pathologically T1 (n = 23) and T2 (n = 8) breast carcinomas. Sonographic measurements demonstrated the highest correlation coefficient (r = 0.84), with the lowest residual standard deviation calculated in relation to the regression line. As a result, real-time sonography yielded the most accurate determination of breast cancer size in this series. Sonographic tumor size determination has proved valuable when mammography failed to delineate the tumor, particularly in patients with dense breasts. It may also be recommended in the evaluation of tumor response to nonsurgical conservative treatment.
Background and Purpose-At 1.5 T, diffusion-weighted imaging-fluid-attenuated inversion recovery (DWI-FLAIR) mismatch helps identify strokes within 4.5 hours of onset. However, at 3T, studies have found divergent results. The goal of this study was to determine whether DWI-FLAIR mismatch at 3T would also be helpful for identifying patients within 4.5 hours of symptom onset. Methods-All patients presenting with an ischemic stroke in the middle cerebral artery territory and explored with 3T MRI within 12 hours between November 2007 and April 2012 were included in this retrospective study. Two readers analyzed the DWI and FLAIR images. Logistic regression was performed to determine independent predictors of FLAIR visibility. Also, the predictive values of a mismatch for identifying patients with stroke onset ≤4.5 hours were estimated. Results-The study included 194 patients. The only predictive factor of FLAIR visibility was delayed MRI acquisition. The DWI-FLAIR mismatch was able to identify patients within 4.5 hours of stroke onset with relatively low sensitivity (0.55; 95% confidence interval, 0.48-0.63), low specificity (0.60; 95% confidence interval, 0.42-0.77), high positive predictive value (0.88; 95% confidence interval, 0.82-0.94), and very low negative predictive value (0.19; 95% confidence interval, 0.11-0.28). In addition, 44.5% of patients had a positive FLAIR sequence within 4.5 hours. Conclusions-This study improves our understanding of DWI-FLAIR mismatch as an imaging biomarker for wake-up management of patients with stroke. At 3T, the presence of a DWI-FLAIR mismatch was able to identify stroke onset of <4.5 hours. from symptom onset within the first 4.5 hours because of low sensitivity. 10The goal of the present study was to determine whether the DWI-FLAIR mismatch at 3T might be a good marker for identifying those patients who are within 4.5 hours of ischemic stroke symptom onset. Materials and Methods PatientsPatients with ischemic strokes in the middle cerebral artery territory who underwent 3T MRI at our institution during the first 12 hours of symptom onset were retrospectively studied during the period from November 2007 to April 2012. They were identified from the registry of the stroke unit. Patients were included if they had a precise time of stroke symptom onset and if they had undergone DWI and FLAIR imaging. The study had the approval of the local institutional review board. According to the study design, written informed consent was waived.Initially, 234 patients were included in the study. Patients with FLAIR images showing major artifacts (n=20; 8.9%) were excluded, as were those with multiple lesions of different ages (n=20; 8.9%), because of the difficulty of attributing lesions to the stroke symptoms used to date it.11 Ultimately, data from 194 patients were analyzed. For each patient, demographic data (sex, age), National Institutes of Health Stroke Scale (NIHSS) score at admission, and stroke symptom onset time to determine the stroke onset-to-MRI delay were collected. MRI Proto...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.